Sign in
RP

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)·Q2 2025 Earnings Summary

Executive Summary

  • Q2 2025 results were steady: net loss of $6.05M and diluted EPS of $0.12, with operating expenses down ~25% year over year as R&D tapered post-OLE trial completion, and EPS matched S&P Global consensus; the company remains pre-revenue .*
  • Clinical narrative strengthened: the full 1-year open-label extension dataset for brilaroxazine showed sustained improvements across PANSS domains and favorable tolerability, supporting pre-NDA dialogue with FDA in Q4 2025 and an accelerated NDA submission target from Q4 2026 to Q2 2026 .
  • Liquidity improved with June capital raise: $10M gross proceeds priced at $0.50 with accompanying warrants; cash increased to $10.4M at quarter-end, though share count rose to ~68.0M, highlighting dilution risk and funding dependence ahead of regulatory milestones .
  • Catalysts: FDA pre-NDA meeting (Q4 2025), clarity on whether RECOVER-2 is required, IND for psoriasis pushed to Q2 2026, and partnership efforts—each could drive stock reaction as regulatory path, timelines, and financing visibility evolve .

What Went Well and What Went Wrong

What Went Well

  • Sustained efficacy and tolerability across 1-year OLE: pooled brilaroxazine showed long-term improvements in PANSS total (-18.1), positive (-5.0), negative (-4.4), and PSP (+11.3), with 35% discontinuation largely due to consent withdrawal/lost to follow-up; management emphasized “differentiated and durable” profile positioning towards registration .
  • Regulatory timeline firmed: pre-NDA meeting planned for Q4 2025 and NDA submission target accelerated to Q2 2026, reflecting confidence that “all key clinical data required for NDA are completed” and reinforcing a path to potential approval .
  • Strengthened capital position: completed a $10M public equity offering in June, supporting R&D and working capital while the company pursues partnerships to advance the pipeline .

What Went Wrong

  • Dilution from financing: shares outstanding increased to 68,003,613 at June 30 from 46,579,199 at year-end, and weighted average shares rose materially year over year, highlighting investor dilution risk as the company bridges to potential approval .
  • Psoriasis IND delayed: timing shifted from “later in 2025” to “by Q2 2026,” extending non-schizophrenia pipeline timelines and potentially limiting near-term optionality beyond the lead indication .
  • Still pre-revenue and burning cash: net loss remained significant ($6.05M in Q2), and cash burn continues despite operating expense reductions; commercialization and revenue remain contingent on regulatory outcomes and financing .

Financial Results

Income Statement and Operating Metrics

MetricQ2 2024 (oldest)Q1 2025Q2 2025 (newest)
Revenue ($USD Millions)$0.00*$0.00*$0.00*
Net Loss ($USD Millions)$7.86 $6.43 $6.05
Diluted EPS ($USD)-$0.26 -$0.13 -$0.12
R&D ($USD Millions)$5.58 $4.11 $3.72
G&A ($USD Millions)$2.55 $2.42 $2.35
Total Operating Expenses ($USD Millions)$8.13 $6.54 $6.07
Weighted Avg Shares (Millions)30.56 48.64 49.85

Balance Sheet Snapshot

MetricQ1 2025Q2 2025
Cash and Equivalents ($USD Millions)$5.29 $10.36
Total Current Liabilities ($USD Millions)$11.51 $12.08
Common Shares Outstanding (Period-End, Millions)46.74 68.00

EPS vs S&P Global Consensus

MetricQ2 2024Q1 2025Q2 2025
EPS Actual ($)-0.26 -0.13 -0.12
EPS Consensus Mean ($)-0.29*-0.21*-0.12*
Primary EPS – # of Estimates4*5*5*
Revenue Consensus Mean ($USD Millions)0.00*0.00*0.00*

Note: *Values retrieved from S&P Global.

Clinical KPIs (RECOVER OLE Dataset)

KPIOLE 6-Month (N=303)OLE 12-Month (N=159)Rollover Double-Blind→OLE 13-Month (N=50)
PANSS Total Score (points)-10.7 -18.1 -47.7
Positive Symptoms (points)-3.3 -5.0 -14.0
Negative Symptoms (points)-2.8 -4.4 -10.5
Negative Marder Factor (points)-3.0 -4.4 —
Personal and Social Performance (points)+4.5 +11.3 +32.7
CGI-S score >1-point37.3% 58.5% 100%
Discontinuation Rate (1-year)—35% —

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
FDA Pre-NDA Meeting (Schizophrenia)Q4 2025Not disclosed in Q1 2025 Planned in Q4 2025 Established (new)
NDA Submission (Schizophrenia)TimingQ4 2026 Q2 2026 Raised/Accelerated
RECOVER-2 (Phase 3 Potential)Timing/RequirementExpected mid-2025, subject to financing Assessing initiation pending FDA recommendation for path to approval Deferred/Pending FDA
Psoriasis IND (Liposomal-Gel)TimingLater in 2025 By Q2 2026 Lowered/Delayed
PartnershipsOngoingPursue partnerships Pursuing partnership opportunities Maintained

Earnings Call Themes & Trends

Note: A Q2 2025 earnings call transcript is not available in our document catalog or via public transcript repositories; commentary below is derived from company releases.

TopicQ4 2024 (P-2)Q1 2025 (P-1)Q2 2025 (Current)Trend
Regulatory Path (NDA)Preliminary OLE data supportive; targeting NDA in Q4 2026 OLE completion, data set expected Q2; NDA target Q4 2026 Full OLE dataset; pre-NDA meeting Q4 2025; NDA target Q2 2026 Accelerating
R&D ExecutionOLE positive preliminary data OLE complete (446 participants), data imminent Robust OLE long-term efficacy and tolerability details Maintained/Strengthened
Funding/DilutionPublic offering ($18M) completed Dec 2024 Cash $5.3M; financing referenced $10M offering in June; cash $10.4M; shares up to 68.0M Increased dilution; improved liquidity
Patent/ExclusivityOngoing protection —Portfolio expansion efforts, potential exclusivity to 2045+ Maintained/Expanded
Additional IndicationsPsoriasis IND later 2025 —Psoriasis IND pushed to Q2 2026 Delayed
PartnershipsPursue partnerships Pursue partnerships Pursuing partnerships Maintained

Management Commentary

  • “The successful completion of our global OLE 1-year trial marks a major milestone… We believe all key clinical data required for NDA are completed… Pending favorable feedback from the FDA, we will target an NDA submission in the second quarter of 2026.” — Laxminarayan Bhat, Ph.D., Founder, President, and CEO .
  • “We are pleased to complete the positive registrational trial for our brilaroxazine program… multiple biomarker data serve as independent measures of efficacy… we look forward to bringing brilaroxazine to more patients globally as fast as possible.” — Laxminarayan Bhat, Ph.D. .
  • External clinical perspectives underscored negative symptom improvements and biomarker-driven efficacy with favorable adherence and side-effect profile .

Q&A Highlights

  • No Q2 2025 earnings call transcript is available; MarketBeat lists a call date/time but does not provide transcript content, and the company’s newsroom contains the press release only .
  • As a result, specific Q&A themes, guidance clarifications, and tone changes versus prior quarters cannot be directly referenced.

Estimates Context

  • EPS matched S&P Global consensus: Q2 2025 actual -$0.12 vs consensus -$0.12; Q1 2025 beat (-$0.13 vs -$0.21); Q2 2024 beat (-$0.26 vs -$0.29). Revenue consensus is $0.00 in all periods given pre-commercial status .*
  • With operating expenses trending lower and clinical data supportive, estimates may shift focus from near-term P&L to regulatory milestones (pre-NDA meeting outcome; RECOVER-2 requirement) and financing runway, rather than modelable revenue/EPS until potential approval .*

Note: *Values retrieved from S&P Global.

Key Takeaways for Investors

  • EPS was in line with S&P Global consensus for Q2 2025; operating expenses fell materially YoY as R&D tapered post-OLE, narrowing quarterly losses without product revenue .*
  • The full 1-year OLE dataset strengthens the efficacy/tolerability profile across PANSS domains and supports the pre-NDA meeting in Q4 2025—an inflection point for clarity on the need/timing of RECOVER-2 and NDA submission .
  • Liquidity improved with a $10M raise, lifting cash to $10.4M at quarter-end, but share count increased to ~68.0M, underscoring dilution risk until non-dilutive capital or partnerships materialize .
  • Regulatory guidance accelerated: NDA target moved from Q4 2026 to Q2 2026, signaling confidence in the data package; investors should watch the Q4 FDA feedback for gating risks .
  • Non-schizophrenia pipeline timelines lengthened (psoriasis IND now Q2 2026), focusing near-term narrative squarely on schizophrenia approval and potential label strategy .
  • Upcoming catalysts (FDA meeting, potential RECOVER-2 path, partnerships) will drive sentiment and could re-rate the stock if they reduce approval uncertainty and financing overhang .
  • Tactical stance: trade around regulatory events and capital formation updates; medium-term thesis hinges on brilaroxazine differentiation (negative symptom efficacy, biomarker support) translating into approval and a viable launch pathway .
Note: *Values retrieved from S&P Global.